Salix Pharmaceuticals, Ltd. (SLXP) issued an update on its FY13 earnings guidance on Thursday morning. The company provided EPS guidance of approx $3.37 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.37. The company issued revenue guidance of approx $920 million, compared to the consensus revenue estimate of $917.15 million.
Salix Pharmaceuticals, Ltd. (SLXP) traded up 0.12% on Thursday, hitting $48.85. Salix Pharmaceuticals, Ltd. (SLXP) has a 1-year low of $37.52 and a 1-year high of $55.99. The stock’s 50-day moving average is currently $47.69. The company has a market cap of $2.874 billion and a price-to-earnings ratio of 37.85.
Salix Pharmaceuticals last released its earnings data on Thursday, February 28th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.03. The company had revenue of $198.17 million for the quarter, compared to the consensus estimate of $199.85 million. During the same quarter last year, the company posted $1.18 earnings per share. Salix Pharmaceuticals’s revenue was up 27.7% compared to the same quarter last year. Salix Pharmaceuticals has set its FY13 guidance at approx $3.37 EPS. Analysts expect that Salix Pharmaceuticals, Ltd. (SLXP) will post $3.19 EPS for the current fiscal year.
A number of analysts have recently weighed in on SLXP shares. Analysts at Janney Montgomery Scott initiated coverage on shares of Salix Pharmaceuticals in a research note to investors on Thursday, January 31st. They set a buy rating and a $55.00 price target on the stock. On a related note, analysts at RBC Capital initiated coverage on shares of Salix Pharmaceuticals in a research note to investors on Friday, January 11th. They set an outperform rating and a $53.00 price target on the stock. Finally, analysts at Zacks reiterated a neutral rating on shares of Salix Pharmaceuticals in a research note to investors on Friday, January 4th. They now have a $46.00 price target on the stock.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal diseases, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.